Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Invested Capital (2019 - 2026)

C4 Therapeutics has reported Invested Capital over the past 8 years, most recently at $234.2 million for Q1 2026.

  • For Q1 2026, Invested Capital rose 20.04% year-over-year to $234.2 million; the TTM value through Mar 2026 reached $234.2 million, up 20.04%, while the annual FY2025 figure was $256.6 million, 18.8% up from the prior year.
  • Invested Capital for Q1 2026 was $234.2 million at C4 Therapeutics, down from $256.6 million in the prior quarter.
  • Over five years, Invested Capital peaked at $365.3 million in Q1 2022 and troughed at $154.4 million in Q3 2025.
  • A 5-year average of $253.5 million and a median of $246.1 million in 2023 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: soared 38.52% in 2022 and later plummeted 36.37% in 2025.
  • Year by year, Invested Capital stood at $300.7 million in 2022, then fell by 18.16% to $246.1 million in 2023, then fell by 12.24% to $216.0 million in 2024, then increased by 18.8% to $256.6 million in 2025, then fell by 8.71% to $234.2 million in 2026.
  • Business Quant data shows Invested Capital for CCCC at $234.2 million in Q1 2026, $256.6 million in Q4 2025, and $154.4 million in Q3 2025.